XOMA

XOMAPhase 3

Berkeley, United StatesFounded 1981xoma.com

XOMA has strategically transformed from a traditional drug developer into a capital-efficient royalty aggregator, building a diversified portfolio of economic interests in innovative therapeutic candidates. The company's model mitigates traditional biotech risks by acquiring rights to potential future payments from partnered programs, many of which are advanced by well-funded biopharma partners. XOMA's deep expertise in antibody science informs its investment decisions, targeting programs with validated biology and significant commercial potential across various therapeutic areas.

Market Cap

$209.8M

Founded

1981

Employees

11-50

Focus

Biotech

XOMA · Stock Price

USD 17.651.95 (-9.95%)

Historical price data

AI Company Overview

Technology Platform

A royalty aggregation platform leveraging deep antibody and biologics expertise to acquire economic rights (milestones, royalties) to partnered therapeutic candidates, primarily in late-stage development or commercialized.

Pipeline Snapshot

26 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Placebo + Dose 1 gevokizumab + Dose 2 gevokizumab	Uveitis	Phase 3
gevokizumab + Placebo + gevokizumab open-label	Pyoderma Gangrenosum	Phase 3
Dose 2 gevokizumab	Uveitis	Phase 3
Placebo + Gevokizumab	Behcet's Disease Uveitis	Phase 3
gevokizumab	Pyoderma Gangrenosum	Phase 3

Funding History

Total raised: $50M

Debt$50MHercules CapitalMar 15, 2014

Opportunities

Significant opportunities exist to expand the royalty portfolio by acquiring rights to additional late-stage assets, particularly in underserved therapeutic areas.

The growing trend of biotech companies seeking non-dilutive financing creates a robust deal flow.

Furthermore, the successful commercialization of existing assets like Tepezza provides a growing revenue base to fund new acquisitions.

Risk Factors

Key risks include dependence on partner execution, clinical failure of key portfolio assets, competition for acquiring attractive royalties, potential patent challenges, and the need for future capital raises which could dilute shareholders.

Competitive Landscape

XOMA competes with large royalty acquisition firms like Royalty Pharma and Healthcare Royalty Management. Its differentiation lies in its deep scientific expertise for due diligence and its legacy as a developer, which fosters unique deal flow. It must compete on price, terms, and speed of execution to secure the most promising assets.

Publications

Patents

Pipeline